This phase II study evaluated the toxicity and efficacy of docetaxel and carboplatin as salvage therapy in 36 patients with relapsed, platinum-sensitive ovarian cancer. The most common and significant toxicity was hematologic. The best response was seen in patients with ‡ 1-year remission before relapse. Background: The optimal therapy to treat relapsed, platinum-sensitive ovarian cancer remains elusive. Because most patients receive initial therapy with paclitaxel and platinum, there is a lack of cross-reaction of docetaxel and paclitaxel and retreatment with platinum is standard of care; we evaluated the toxicity and efficacy of docetaxel and carboplatin as salvage therapy for relapsed, platinum-sensitive ovarian cancer. Materials and Methods: This phase II study treated the first-relapsed, platinum-sensitive, stage III/IV ovarian cancer patients with docetaxel 80 mg/m 2 intravenous (IV) over 60 minutes followed by carboplatin area under the curve 6 IV over 30 minutes every 21 days, for 6 cycles. End points were toxicity, response rates, relapse rates, event-free survival, and survival rates. Results: Thirty-six patients were enrolled and 35 were evaluable. Twenty-three percent of patients were age ! 70 years. A total of 170 cycles of therapy were given. Ten patients required dose reduction. Thirty-eight percent had a delay in starting subsequent planned cycles. Most delays were due to hematologic recovery. Hematologic toxicity was most common and significant; 77% grade 4 neutropenia. One patient died from typhilitis. Total complete remission (38%) and partial remission (27%) rate was 65%. Median time to progression was 261 days (60-717). Five (14%) patients remain alive without ovarian cancer, with median follow-up of 5.1 years. Patients who entered the study with ! 12-month duration of initial remission had best response. Conclusion: The combination of docetaxel and carboplatin has toxicity, especially hematologic, and requires growth factor support and close monitoring for infections. Its role for treating ovarian cancer patients was better in patients in whom initial response to therapy was ! 12 months.
Introduction
In spite of recent advances in the treatment of advanced ovarian cancer, most patients still succumb to the disease. The optimal therapy to treat relapse disease remains elusive. For patients with platinum-sensitive, relapsed disease, the standard of care is to retreat with platinum-based therapy. Because there is a lack of crossreaction between docetaxel and paclitaxel 1 and docetaxel has activity in ovarian cancer, 2, 3 it seemed reasonable to study a combination of docetaxel and carboplatin as salvage therapy. This study investigated a regimen similar to that used by Belani in a lung cancer study. 4 It should be noted that while this study was conducted, both ICON4/AGO Ovarian 2.2 trial and AGO OVAR 2/5 trial published the results of their clinical trials that confirm the advantage of doublet platinum/ carboplatinebased combination chemotherapy over monotherapy therapy. 5, 6 Patients and Methods
Thirty-six patients with the first-relapsed, platinum-sensitive stage III/IV advanced ovarian cancer were enrolled to be treated with docetaxel and carboplatin. One patient was not treated on study. Patients were eligible for this clinical trial if they had relapsed > 6 months from completion of platinum therapy. Patients could be treated on the basis of an elevated serum CA 125 (! 100, confirmed by 2 blood tests at least 1 week apart) and/or evidence of measurable disease by physical examination or radiographic (computed tomography [CT]) evaluation. Patients needed to have a platelet count ! 100,000 cells/mL, absolute neutrophil count ! 1500 cells/mL, Karnofsky score ! 60, creatinine clearance > 50 cc/minute, and serum creatinine 2.0 mg/dL, total bilirubin < upper limit normal (ULN), and alanine aminotransferase and aspartate aminotransferase 5 Â ULN with normal alkaline phosphatase. Patients were excluded from therapy if HIV seropositive, had poorly controlled arrhythmias, left ventricle ejection fraction 50%, uncontrolled coronary artery disease or myocardial infarction within the last year, or peripheral neuropathy > grade 2.
Signed consent was obtained from all patients treated through Puget Sound Oncology Consortium. Protocol was approved by Fred Hutchinson Cancer Research Center (FHCRC) Institutional Review Board (IRB) and by the IRB of the hospital where therapy was administered.
Definitions
Patients were restaged nonsurgically before administration of therapy. Complete baseline staging included chest x-ray, CT abdomen/pelvis, physical examination, and CA 125 blood test. All patients were restaged after third and sixth cycles of therapy. Thereafter, they had CA 125 tested every 3 months for the first 2 years, then every 6 months until disease progression or death, and they had CTs every 6 months for the first 2 years and then yearly until disease progression or death.
Duration of response was calculated from beginning of therapy. Responses were defined as complete remission (CR) if there was a disappearance of all gross evidence of disease and normalizations of CA 125 for at least 4 weeks in patients with measurable disease or normalization in patients with CA 125 elevated alone as evidence of disease for 4 weeks. Partial remission (PR) was defined as ! 50% reduction in product obtained after measurement of each lesion for at least 4 weeks or ! 50% decrease in CA 125 in patients with only elevated CA 125 for 4 weeks. Progression of disease was defined as ! 50% increase in product of any previously documented lesion, appearance of new lesions, or ! 50% increase in CA 125 within 8 weeks of entry into study. Stable disease was defined as any condition that did not meet the previously defined criteria.
Treatment Schedule
Docetaxel 80 mg/m 2 by 1-hour infusion intravenous (IV) followed by carboplatin area under the curve 6 IV infusion over 30 minutes was administered every 21 days, with plan to give at least 6 cycles. Premedication with dexamethasone 8 mg twice daily for 3 days was begun 24 hours before infusion of docetaxel. Carboplatin dose was calculated based on 6 Â (24 hour measured creatinine urine clearance þ 25). Dose of carboplatin was recalculated for each cycle. Antiemetics, including 5-HT antagonists, were recommended. Initially, granulocyte -colony stimulating factor support was allowed if patients developed febrile neutropenia, sepsis that required IV antibiotics, ANCs fell 1000 to 1500 after 2 to 3 weeks' delay, or ANC 500 for 7 consecutive days. When degree of neutropenia was seen in the first group of patients, all patients received Neulasta (pegfilgrastim) 6 mg with each cycle of chemotherapy.
There were dose reductions in docetaxel and carboplatin for delay of initiation of therapy because of decreased platelet and neutrophil count, neurologic toxicity > grade 2, ! 50% in serum creatinine, and increased serum transaminases. The lowest dose for carboplatin was area under the curve 4 and for docetaxel was 60 mg/m 2 . Patients were withdrawn from treatment on study if they developed ! grade 4 neurologic toxicity, ! grade 3 nonhematologic/non-neurologic (except increased transaminases and fatigue) or if there was a delay > 3 weeks from receiving the next cycle for any major toxicity. Therapy could not be given until platelet count recovered to ! 100,000 cells/mL and neutrophil count ! 1500 cells/mL. Regimen-related toxicity grading was per National Institutes of Health/National Cancer Institute common toxicity criteria, 1998 version.
Statistics
Actuarial probabilities of survival and event-free survival (EFS) were computed according to Kaplan and Meier. 7 Survival was calculated from start of the first cycle of therapy until death or date of last contact. The end point for EFS was relapse, second cancer, or death. Patients who never achieved a CR, PR, or stable were considered to have relapsed on day 1 after the first cycle of therapy.
The median follow-up of all patients was 1862 days.
Results

Patient Characteristics
No patients had received docetaxel before enrollment to the study. All patients had been previously treated with paclitaxel and carboplatin or carboplatin alone. Five patients had been also treated previously with gematabine, 1 with topotecan and 1 with cyclophosphamide. One patient received intraperitoneal chemotherapy. Twenty-three percent of patients were aged ! 70 years. Twenty-two patients had soft tissue involvement, including lung, liver, spleen, kidney, or lymph node involvement above or below diaphragm by CT criteria (Table 1 ).
Delivery of Scheduled Therapy
A total of 170 cycles of therapy were given. One patient was enrolled, but referring oncologist never started study therapy; thus, 35 patients are evaluable. Twenty-six patients (74%) completed planned 6 cycles of therapy. One patient died of regimen-related toxicity from typhilitis complications with her first cycle of therapy. One had therapy discontinued because of dose-limiting toxicity; although, of note, the treating physician retreated with study regimen when patient recovered from acute toxicity. Seven patients had progression of disease while on therapy. Ten of 35 evaluable patients (29%) required dose reduction in docetaxel or carboplatin. Thirteen of 35 evaluable patients (38%) had a delay in starting subsequent cycle beyond 3 weeks. Most of these delays were caused by hematologic recovery.
Toxicity
Fourteen patients were hospitalized during therapy. Nine patients received erythropoietin, 1 patient received platelet transfusions, and 6 patients received red blood cell transfusions. The incidence of grades 2 to 5 toxicity is listed in Table 2 .
First-Relapsed, Platinum-Sensitive Ovarian Cancer
Hematologic suppression was most common and significant. Twenty-seven of 35 patients (77%) developed grade 4 neutropenia and 4 of 35 (11%) grade 3 neuropenia. Twenty of 35 patients (57%) had grade 2/3 anemia. Four of 35 patients (11%) had grade 2/3 thrombocytopenia. Most common other toxicity was fatigue. Eleven percent developed grade 2 neurologic toxicity. Forty-six percent manifested grade 2/3 gastrointestinal complaints, including stomatitis, nausea, vomiting, and diarrhea. Nineteen of 35 patients (54%) had grade 2/3 infection. See Table 3 for types of infections. One patient died of infectious complications from typhilitis.
Response
The best response obtained was 13 of 35 evaluable patients (38%) achieving CR and 9 patients of 34 (27%) achieving PR, for a total of 65% CR or PR rate. The median time to disease progression was 261 days (60 to 717 days). Twenty-nine patients have relapsed and all have died of complications of disease progress. Thirty patients have died: 29 of progressive ovarian cancer, including 2 from brain metastases, and 1 from treatment-related typhilitis. The actuarial probabilities of survival and EFS for all patients were delineated in Figures 1 and 2 . Of note, 5 patients (14%) remain alive without ovarian cancer, with median follow-up of 5.1 years. In the patients who entered the study with < 12 months of duration of remission, all patients have relapsed and died. Five of 23 patients (22%) who entered the study with ! 12 months of duration of initial remission remain alive and in remission.
Discussion
A regimen of docetaxel and carboplatin was administered to firstrelapsed, platinum-sensitive, advanced ovarian cancer patients. A dose schedule was adapted from the Belani phase I study developed for lung cancer patients and used for its intensiveness and lack of cross-reacting with the prior paclitaxel therapy. 4 With this drug schedule, the most common significant toxicity was neutropenia, with 77% of patients experiencing grade 4 neutropenia. We had one infectious death, second to complication of typhilitis, after the first cycle of therapy. About 12% of patients developed grade 2 neurologic toxicity, and 46% had grade 2/3 gastrointestinal complaints.
All patients who relapsed < 12 months from completion of initial course of therapy have since relapsed and died. Twenty-two percent of patients who relapsed ! 12 months from completion of initial course of therapy remain alive and in CR, with a median of 5.1-year follow-up. Since we started our study, there have been other drug schedules studied for combining docetaxel and carboplatin. 8, 9 Neutropenia grade 3/4 was seen in 60% of the patients with a CR and PR rate of 72%. Twelve percent of patients had grade 3/4 diarrhea. Of note, The treatment schedule of docetaxel and carboplatin in our study has toxicity, especially hematologic, and the scheduled dose requires growth factor support and close monitoring for infections. Whether our schedule has a role in treating advanced ovarian cancer patients depends on whether there are continued durable responses in the patients to date doing well and whether it is reasonable for patients with more advanced, bulking, relapsed disease to accept a higher risk First-Relapsed, Platinum-Sensitive Ovarian Cancer of toxicity for better chance for debulking therapy. Of note, although relapse remains a problem in most patients, the question of adding maintenance therapy with the newer biological modifiers after adequate debulking remains to be explored.
Conclusion
Docetaxel and carboplatin can be used as salvage therapy to treat the first-relapsed, platinum-sensitive Stage III/IV advanced ovarian cancer patients. Five patients (14%) remain alive without ovarian cancer, with a median follow-up period of 5.1 years.
Clinical Practice Points
Docetexal and carboplatin is an effective salvage therapy for advanced-stage relapsed platinum-sensitive ovarian cancer patients. The regimen has toxicity, especially hematologic, and requires greater support and dose monitoring of patients. Patients who entered the study with ! 12 months duration of initial remission were more likely to remain alive and in remission long term.
